RDPAC Member Firms Invest Over RMB 20 Billion In China In 2006-10
This article was originally published in PharmAsia News
The R&D-based Pharmaceutical Association Committee (RDPAC)'s 37 multinational biopharmaceutical member firms invested over RMB 20 billion ($3.03 billion) in China's drug market during the 11th Five-Year Plan period, according to the committee
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.